ALT/AST increases, and diarrhea, hypothyroidism, and rash are part of known safety profiles of both cabozantinib and nivolumab and were more frequently reported with the combination than with sunitinib in CheckMate 9ER study [11], suggesting potential overlapping toxicity with the combination. This evidence concerns the gene GPT and hypothyroidism.